On March 28, 2011
Some Inconvenient Facts About Yervoy, Bristol-Myers’ New “Holy Grail” Cancer Drug
BMS paid $2.1 billion to acquire a drug that may have cost less than $400 million to develop.
No tags for this post.
0 Comments